304
Views
7
CrossRef citations to date
0
Altmetric
Drug Profile

Certolizumab pegol for the treatment of psoriatic arthritis

&

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Ennio Lubrano, Silvia Scriffignano & Fabio Massimo Perrotta. (2019) TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis. Expert Review of Clinical Immunology 15:12, pages 1303-1312.
Read now
Meghan Woody, Donald Warren, Laura Speck & Julie Jackson. (2017) Leukocytoclastic Vasculitis Drug Reaction to Certolizumab Pegol. Baylor University Medical Center Proceedings 30:2, pages 213-214.
Read now
María Laura Acosta-Felquer, Javier Rosa & Enrique R Soriano. (2016) An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy. Open Access Rheumatology: Research and Reviews 8, pages 37-44.
Read now
Tarannum Jaleel, Craig Elmets, Allison Weinkle, Sama Kassira & Boni Elewski. (2016) Secukinumab (AIN-457) for the treatment of Psoriasis. Expert Review of Clinical Pharmacology 9:2, pages 187-202.
Read now

Articles from other publishers (3)

Rimsha Nooreen, Shweta Nene, Harsha Jain, Velpula Prasannanjaneyulu, Palak Chitlangya, Shivam Otavi, Dharmendra Kumar Khatri, Rajeev Singh Raghuvanshi, Shashi Bala Singh & Saurabh Srivastava. (2022) Polymer nanotherapeutics: A versatile platform for effective rheumatoid arthritis therapy. Journal of Controlled Release 348, pages 397-419.
Crossref
Thelvia I. Ramos, Carlos A. Villacis-Aguirre, Katherine V. López-Aguilar, Leandro Santiago Padilla, Claudia Altamirano, Jorge R. Toledo & Nelson Santiago Vispo. (2022) The Hitchhiker’s Guide to Human Therapeutic Nanoparticle Development. Pharmaceutics 14:2, pages 247.
Crossref
M. Köhm & F. Behrens. (2015) Pharmakotherapie der PsoriasisarthritisPharmacotherapy of psoriatic arthritis. Zeitschrift für Rheumatologie 74:5, pages 398-405.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.